DelveInsight Highlights Myotonic Dystrophy Market Growth Through 2036
LAS VEGAS — September 23, 2026 DelveInsight Business Research, LLP published its latest Myotonic Dystrophy Market Insights report, outlining...
Dyne Therapeutics
Advertisement
Dyne Therapeutics Advances Z-Basivarsen Toward Phase 3 in DM1
WALTHAM, Massachusetts — September 8, 2026 Dyne Therapeutics announced plans to present additional one-year clinical data from the Phase...
Dyne Therapeutics Advances Four DMD Exon-Skipping Candidates
Waltham, Mass., September 3, 2026 Dyne Therapeutics announced that it will present new preclinical data supporting the development of...
Dyne Therapeutics Advances DMD Program with FDA Acceptance
WALTHAM, Mass., July 20, 2026 Dyne Therapeutics, Inc. (Nasdaq: DYN) announced that the U.S. Food and Drug Administration (FDA)...
Dyne Launches Phase 3 HARMONIA Trial for DM1 Therapy
March 08, 2026 — Waltham, Massachusetts, USA Clinical-stage biotechnology innovator Dyne Therapeutics has announced the initiation of the Phase...
Advertisement
